West Pharmaceutical Services (WST) Enterprise Value (2009 - 2026)

West Pharmaceutical Services has disclosed Enterprise Value across 18 years of filings, most recently posting -$521.4 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$521.4 million, down 29.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$521.4 million (down 29.0% YoY), and the FY2025 annual result was -$791.3 million, down 63.29% from the prior year.
• Enterprise Value came in at -$521.4 million for Q1 2026 at West Pharmaceutical Services, up from -$791.3 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$404.2 million in Q1 2025 to a low of -$898.6 million in Q3 2023.
• The 5-year median for Enterprise Value is -$667.7 million (2022), against an average of -$666.1 million.
• Across the five-year window, Enterprise Value soared 45.37% in 2024 and slumped 63.29% in 2025, its largest moves.
• West Pharmaceutical Services' Enterprise Value stood at -$894.3 million in 2022, then gained by 4.52% to -$853.9 million in 2023, then jumped by 43.25% to -$484.6 million in 2024, then plunged by 63.29% to -$791.3 million in 2025, then soared by 34.11% to -$521.4 million in 2026.
• The last three Enterprise Value figures came in at -$521.4 million (Q1 2026), -$791.3 million (Q4 2025), and -$628.5 million (Q3 2025), per Business Quant data.